LWM
ALNY icon

LeConte Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

LeConte Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$230K Buy
695
+91
+15% +$31K 0.15% 123
2025
Q4 		$240K Buy
604
+78
+15% +$34.5K 0.16% 106
2025
Q3 		$240K Buy
+526
New +$214K 0.16% 101

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LeConte Wealth Management's ALNY Position: Q1 2026 in Review

LeConte Wealth Management increased its Alnylam Pharmaceuticals (ALNY) stake by 15% in Q1 2026, buying an estimated $31K and bringing the position to 695 shares worth $230K. The position accounts for 0.15% of the portfolio, ranked #123.

LeConte Wealth Management first reported a position in ALNY in Q3 2025 and has held it in 3 quarters since. The position peaked at $240K in Q4 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • LeConte Wealth Management held 695 shares of Alnylam Pharmaceuticals worth $230K as of Q1 2026.
  • LeConte Wealth Management bought 91 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $31K.
  • Alnylam Pharmaceuticals made up 0.15% of LeConte Wealth Management's portfolio in Q1 2026, its #123 holding.
  • LeConte Wealth Management first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • LeConte Wealth Management's Alnylam Pharmaceuticals position peaked at $240K in Q4 2025.
  • 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on LeConte Wealth Management's 13F filing for Q1 2026, filed 12 May 2026.